Zepbound Side Effects: Withdrawal and Discontinuation Syndrome Explained

Print or save as PDFOpens the printable restart record and your print dialog. No sign-up.

Is there a Zepbound withdrawal syndrome?

Zepbound is tirzepatide, a once-weekly subcutaneous injection that activates both GIP and GLP-1 receptors [1]. Its warnings section covers thyroid C-cell tumors (the boxed warning), severe gastrointestinal reactions, acute kidney injury from volume depletion, gallbladder disease, pancreatitis, serious hypersensitivity, hypoglycemia, diabetic retinopathy complications, and pulmonary aspiration during anesthesia or deep sedation [1]. Its adverse reactions section lists what is common: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and GERD [1]. Neither section describes dependence or a withdrawal syndrome [1].

Tirzepatide lowers calorie intake, likely through appetite, and it delays gastric emptying [1].

What SURMOUNT-4 showed about stopping

SURMOUNT-4 tested what happened to participants' weight when they continued tirzepatide or switched to placebo [2]. In SURMOUNT-4, 783 adults without diabetes received open-label tirzepatide at a maximum tolerated dose of 10 or 15 mg for 36 weeks [2]. The 670 who completed that phase had lost a mean 20.9% of body weight, and they were randomized to keep taking tirzepatide or switch to placebo for 52 more weeks [2]. From week 36 to week 88, mean weight changed by -5.5% with continued tirzepatide and +14.0% with placebo, a difference of 19.4 percentage points [2]. Of the 670 randomized participants, 71% were women [2].

After switching to placebo, participants regained substantial weight over 52 weeks: a mean 14.0% from their week-36 weight, while those who continued tirzepatide lost a further 5.5% [2]. Participants assigned to placebo stopped tirzepatide at week 36 rather than tapering [2].

Does appetite come back after stopping?

Tirzepatide decreases calorie intake, likely through appetite, and delays gastric emptying [1]. SURMOUNT-4's primary endpoint was the mean percent change in body weight from week 36 to week 88 [2].

Tirzepatide has a half-life of approximately 5 days and reaches steady state after 4 weeks of weekly dosing [1]. The regain in SURMOUNT-4 was measured across the 52 weeks after the switch, with a mean gain of 14.0% [2].

The label also notes that the delay in gastric emptying is largest after the first dose and diminishes over time [1].

Do the GI side effects change after the last dose?

In the pooled weight-management trials, any gastrointestinal adverse reaction was reported by 56% of patients at every Zepbound dose versus 30% on placebo [1]. The label states that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1].

Mood after stopping

The current Zepbound label (effective August 2026) contains no mention of suicidal behavior or ideation [1].

Is there a way to taper off Zepbound?

The label's dosing section gives the starting schedule: 2.5 mg once weekly for 4 weeks, described as treatment initiation and not an approved maintenance dose, then increases in 2.5 mg steps after at least 4 weeks, with maintenance doses of 5, 10 or 15 mg for weight reduction and 10 or 15 mg for obstructive sleep apnea, and a maximum of 15 mg weekly [1]. It covers starting, escalating, missed doses and injection technique, and gives no schedule for tapering off [1].

Does the label give a restart dose after a break?

The Zepbound label specifies 2.5 mg once weekly for the first four weeks of treatment but does not give a separate restart schedule after a break [1]. It states that 2.5 mg is for treatment initiation and is not approved as a maintenance dose; maintenance for weight reduction is 5, 10 or 15 mg weekly, and 15 mg weekly is the maximum [1].